Table 1.

Baseline clinical features of patient-derived cancer cells.

No.	Cancer types	Date of collection	Age	Sex	Source	Pathology	Gene	Clinical treat	CNV gene
PDC#01	AGC	2016-11-01	61	M	Stomach	Adenocarcinoma	HER2 (3+)	Lapatinib	MYC
PDC#02	AGC	2017-12-15	54	F	Ascites	Tubular adenocarcinoma	HER2 (3+)	Lapatinib	None
PDC#03	AGC	2016-11-01	65	M	Ascites	Adenocarcinoma, moderately differentiated	HER2 (3+)	Lapatinib	ERBB2
PDC#04	AGC	2016-11-25	73	M	Ascites	Tubular adenocarcinoma, moderately differentiated	HER2 (3+)	x	analysis
PDC#05	AGC	2017-12-27	47	M	Lymph node	Tubular adenocarcinoma, moderately differentiated	HER2 (3+), MSH2, MLH1	Herceptin resistant	ERBB2, CCNE1
PDC#06	AGC	2017-10-02	69	F	Stomach	Tubular adenocarcinoma, poorly differentiated	MET (+)	Volitinib	MET, ERBB2
PDC#07	AGC	2017-11-01	63	M	Stomach	Poorly differentiated adenocarcinoma, Favor adenocarcinoma	MET (3+), TSC1, TSC2, MLH1, ATM	Volitinib	MET, MYC
PDC#08	AGC	2017-11-01	43	F	Stomach	Metastatic carcinoma	MET amplification	Volitinib	MET